A combination of Aduro BioTech's immunotherapy vaccine CRS-207 and GVAX Pancreas irradiated, granulocyte-macrophage colony–stimulating factor vaccine secured breakthrough designation from the FDA as a treatment for metastatic pancreatic cancer. The designation was granted based on midstage trial data that showed patients who took the vaccine combination survived longer than those who took GVAX Pancreas vaccine alone.
Evotec granted AstraZeneca rights to a series of compounds for development involving chronic kidney disease. The partners aim to identify effective treatments that stop or slow the decline of kidney function. The deal entitles Evotec to an upfront payment, research funding, milestone fees and sales royalties.
Voter support for Washington state's Initiative 522, which would require labeling of biotech foods, dropped by 20 percentage points while opposition increased by 21 points, according to a survey of 413 likely voters carried out by Elway Poll. The poll, conducted from Oct. 15 to 17, found that 46% of voters supported the initiative, 42% opposed it and 12% were undecided. The initiative is now considered too close to call.
Azevan Pharmaceuticals, which specializes in developing treatments for mood and behavior disorders, secured $2.2 million in financing, a regulatory filing showed. The money will support midstage trials for two neurological disease candidates. The company also received $600,000 from the NIH.
KiOR has received new commitments of $85 million from a venture fund run by Vinod Khosla and $15 million from a Bill Gates fund. The investments will improve KiOR's cash flow and support development of a second cellulosic ethanol production facility, the company said.